MedTrace Logo

Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease

NCT07298343 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 356

Last updated 2026-04-02

No results posted yet for this study

Summary

A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet

Conditions

Interventions

DRUG

ZED1227 + SIGE

oral treatment with different daily doses of ZED1227 vs placebo

OTHER

Placebo

Placebo + SIGE

Sponsors & Collaborators

  • Takeda Development Center Americas, Inc.

    collaborator INDUSTRY

  • Dr. Falk Pharma GmbH

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-10
Primary Completion
2027-08-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07298343 on ClinicalTrials.gov